Chronic kidney disease (CKD) in the elderly - A geriatrician's perspective

Aging Male

Volumn 10, Issue 3, 2007, Pages 113-137

  Munikrishnappa, Devaraj ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Dialysis; Elderly aged; Frailty; Kidney failure insufficiency

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLONIDINE; CLOPIDOGREL; CYSTINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GUANABENZ; GUANFACINE; IRON; LACIDIPINE; LISINOPRIL; METHYLDOPA; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANDOLAPRIL; TRIMETHOPRIM; VERAPAMIL;

ANEMIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ELDERLY CARE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY INJURY; MATHEMATICAL ANALYSIS; PAIN; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RENAL DIABETES; REVIEW; RISK FACTOR; URINARY EXCRETION;

AGED; AGING; BIOLOGICAL MARKERS; DIALYSIS; FRAIL ELDERLY; GERIATRIC NURSING; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; UNITED STATES;

EID: 34547943090     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530701419096     Document Type: Review

References (202)

1. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57.
2. US Renal Data System. USRDS 2004 annual data report. Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. http://www.usrds.org/atlas_2004.htm. Accessed 20.7.2006.
3. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
4. US Renal Data System: USRDS 2003 annual data report: atlas of end stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney diseases. 2003.
5. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-2758.
6. Hansberry MR, Whittier WL, Krause MW. The elderly patient with chronic kidney disease. Adv Chronic Kidney Dis 2005;12:71-77.
7. Lamb EJ, O'Riordan SE, Delaney MP. Kidney function in older people: pathology, assessment and management. Clin Chim Acta 2003;334:25-40.
8. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004;43:825-835.
9. US Renal Data System: USRDS 2006 Annual Data Report: atlas of end stage renal disease in the United States, National Institute of Health, National Institute of Diabetes & Digestive Kidney Diseases. 2006 Bathesda, MD. Chapter 1. Chronic kidney disease p47-64. Accessed at: http://www.usrds.org/ 2006/pdf/01_ckd_06.pdf. Accessed 24.12.2006.
10. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006;70:1694-1705.
11. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996;49:800-805.
12. Weller JM, Wu SC, Ferguson CW, Hawthorne VM. End-stage renal disease in Michigan. Incidence, underlying causes, prevalence, and modalities of treatment. Am J Nephrol 1985;5:84-95.
13. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934-2941.
14. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003;10:3-14.
15. Gandolfo MT, Verzola D, Salvatore F, Gianiorio G, Procopio V, Romagnoli A, et al. Gender and the progression of chronic renal diseases: does apoptosis make the difference? Minerva Urol Nefrol 2004;56:1-14.
16. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001;10:219-225.
17. Morley JE, Haren MT, Rolland Y, Kim MJ. Frailty. Med Clin North Am 2006;90:837-847.
18. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
19. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:255-263.
20. Walston J, Fried LP. Frailty and the older man. Med Clin North Am 1999;83:1173-1194.
21. Fried LP, Newman A, Walston J, et al. Frailty and mortality in the cardiovascular health study. Report presented at 51st Annual Scientific Meeting of the Gerontological Society of America, Philadelphia, November 1998.
22. Newman A, Walston J, Hirsch C, et al. Physiologic correlates of frailty in the cardiovascular health study cohort. Report presented at 51st Annual Scientific Meeting of the Gerontological Society of America, Philadelphia, November 1998.
23. Morley JE, Kaiser FE, Sih R, Hajjar R, Perry HM, III. Testosterone and frailty. Clin Geriatr Med 1997;13:685-695.
24. Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993;84:95-98.
25. Morley JE, Perry HM, III, Kaiser FE, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149-152.
26. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-1177.
27. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-1667.
28. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
29. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269:E820-E826.
30. Morley JE. An overview of diabetes mellitus in older persons. Clin Geriatr Med 1999;15:211-224.
31. Rodriguez-Saldana J, Morley JE, Reynoso MT, Medina CA, Salazar P, Cruz E, et al. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc 2002;50:111-116.
32. Miller DK, Lui LY, Perry HM, III, Kaiser FE, Morley JE. Reported and measured physical functioning in older innercity diabetic African Americans. J Gerontol A Biol Sci Med Sci 1999;54:M230-M236.
33. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 2004;43:861-867.
34. McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant 2006;21:2210-2216.
35. Kovesdy CP, Trivedi BK, Anderson JE. Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis 2006;13:183-188.
36. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047.
37. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
38. Besarab A, Ross RP, Nasca TJ. The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 1995;4:155-161.
39. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10:1793-1800.
40. Ismail N. Hemodialysis in the elderly. UpToDate, 2006. Accessed at: http://www.utdol.com/utd/content/topic.do? topicKey=dialysis/19941&type= A&selectedTitle=25~289. Accessed 20.7.2006.
41. Loos C, Briancon S, Frimat L, Hanesse B, Kessler M. Effect of end-stage renal disease on the quality of life of older patients. J Am Geriatr Soc 2003;51:229-233.
42. Abrass CK. Renal disease in the elderly. Best Practice of Medicine 1999. Accessed at: http://merck2.micromedex.com/index.asp?page= bpm_cited&article_id=CPM01NP277. Accessed 31.1.2006.
43. Huisman RM. The deadly risk of late referral. Nephrol Dial Transplant 2004;19:2175-180.
44. O'Riordan S. Chronic kidney disease and older people - implications of the publication of the Part 2 of the National Service Framework for Renal Services. Age Ageing 2005;34:546-548.
45. Epstein M. Aging and the kidney. J Am Soc Nephrol 1996;7:1106-1122.
46. Choudhury D, Raj DSC, Levi M. Effect of aging on renal function and disease. In: Brenner & Rector's. The kidney, 7th ed. Philadelphia, PA Saunders;2004:2305-2321.
47. Takazakura E, Sawabu N, Handa A, Takada A, Shinoda A, Takeuchi J. Intrarenal vascular changes with age and disease. Kidney Int 1972;2:224-230.
48. Davison AM. Renal disease in the elderly. Nephron 1998;80:6-16.
49. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-285.
50. Godin M, Moulin B, Etienne I, Fillastre JP. [Renal aging in man]. Presse Med 1992;21:1246-1248.
51. Macias Nunez JF, Garcia IC, Bondia RA, Rodriguez Commes JL, Corbacho BL, Tabernero Romo JM, et al. Renal handling of sodium in old people: a functional study. Age Ageing 1978;7:178-181.
52. Luft FC, Fineberg NS, Miller JZ, Rankin LI, Grim CE, Weinberger MH. The effects of age, race and heredity on glomerular filtration rate following volume expansion and contraction in normal man. Am J Med Sci 1980;279:15-24.
53. Fliser D, Zeier M, Nowack R, Ritz E. Renal functional reserve in healthy elderly subjects. J Am Soc Nephrol 1993;3:1371-1377.
54. MacGregor MS, Boag DE, Innes A. Chronic kidney disease: evolving strategies for detection and management of impaired renal function. QJM 2006;99:365-375.
55. NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm 2002, 2006.
56. Hall PM. Proteinuria. The Cleveland Clinic. Center for Continuing Education. Accessed at: http://www.clevelandclinicmeded.com/diseasemanagement/ nephrology/proteinuria/proteinuria.htm. Accessed 20.8.2006.
57. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4. Definition and Classification of Stages of Chronic Kidney Disease. Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class_g1.htm. Accessed 11.3.2006.
58. Stevens LA, Levey AS. Clinical implications of estimating equations for glomerular filtration rate. Ann Intern Med 2004;141:959-961.
59. Kelleher CL, Lindeman RD. Kidney Diseases and Disorders (chapter 50). Pompei P, Murphy JB, eds. Geriatrics review syllabus: a core curriculum in geriatric medicine, sixth edition. New York, NY: American Geriatrics Society; 2006.
60. Stevens L, Perrone DR. Assessment of kidney function: serum creatinine; BUN; and GFR. UpToDate 2006. Version 14.3. Accessed at: http://www.utdol.com/ utd/content/topic.do?topicKey=fldlytes/32110&type=A&selectedTitle=1~30. Accessed 10.12.2006.
61. O'Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003;40:648-655.
62. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003;163:356-360.
63. Fraser CG. Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta 2004;346:19-24.
64. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-550.
65. Stevens LA, Levey AS. Chronic kidney disease in the elderly-how to assess risk. N Engl J Med 2005;352:2122-2124.
66. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246.
67. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18:2024-2031.
68. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-318.
69. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
70. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003;63:1944-1947.
71. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 2003;49:680-681.
72. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003;338:87-90.
73. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003;42:36-43.
74. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de ZD, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
75. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006;48:712-719.
76. Coresh J, Astor B. Decreased kidney function in the elderly: clinical and preclinical, neither benign. Ann Intern Med 2006;145:299-301.
77. Macisaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006;49:1686-1689.
78. Pedone C, Corsonello A, Incalzi RA. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006;35:121-126.
79. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
80. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
81. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol Dial Transplant 2003;18:1446-1451.
82. Kidney Health Australia. National Chronic Kidney Disease Strategy. Accessed at: http://www.kidney.org.au/?section=86&subsection=544. Accessed 28.8.2006.
83. Bertolatus JA, Goddard L. Evaluation of renal function in potential living kidney donors. Transplantation 2001;71:256-260.
84. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002;13:2140-2144.
85. Kuan Y, Hossain M, Surman J, El Nahas AM, Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant 2005;20:2394-2401.
86. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003;14:2573-2580.
87. Pierrat A, Gravier E, Saunders C, Caira MV, it-Djafer Z, Legras B, et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 2003;64:1425-1436.
88. Poggio ED, Wang X, Greene T, Van LF, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005;16:459-466.
89. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-937.
90. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 2004;43:112-119.
91. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant 2002;17:2036-2037.
92. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002;17:1909-1913.
93. Van Den Noortgate NJ, Janssens WH, Delanghe JR, Afschrift MB, Lameire NH. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc 2002;50:1278-1282.
94. Lamb EJ, Webb MC, Simpson DE, Coakley AJ, Newman DJ, O'Riordan SE. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement? J Am Geriatr Soc 2003;51:1012-1017.
95. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004;38:73-77.
96. Clase CM, Garg AX, Kiberd BA. Classifying kidney problems: can we avoid framing risks as diseases? BMJ 2004;329:912-915.
97. Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000;35:433-447.
98. Modesto-Segonds A, Ah-Soune MF, Durand D, Suc JM. Renal biopsy in the elderly. Am J Nephrol 1993;13:27-34.
99. Preston RA, Stemmer CL, Materson BJ, Perez-Stable E, Pardo V. Renal biopsy in patients 65 years of age or older. An analysis of the results of 334 biopsies. J Am Geriatr Soc 1990;38:669-674.
100. Pharmacological therapy: use of antihypertensives in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Accessed at: http://www.kidney.org/professionals/KDOQI/ guidelines_bp/guide_7.htm. Accessed 10.12.2006.
101. Use of diuretics in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Accessed at: http://www.kidney. org/professionals/KDOQI/guidelines_bp/guide_12.htm. Accessed 10.12.2006.
102. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in CKD. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Accessed at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/guide_11.htm. Accessed 9.12.2006.
103. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990;112:707-708.
104. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912-919.
105. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
106. Bohlen L, de Court, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:84S-92S.
107. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283-1289.
108. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993;21:113-1118.
109. Pharmacological therapy: diabetic kidney disease. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Accessed at: http://www.kidney.org/professionals/KDOQI/ guidelines_bp/guide_8.htm. Accessed 9.12.2006.
110. Pharmacological therapy: nondiabetic kidney disease. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Accessed at: http://www.kidney.org/professionals/KDOQI/ guidelines_bp/guide_9.htm. Accessed 9.12.2006.
111. Association of chronic kidney disease with diabetic complications. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Accessed at: http://www.kidney.org/ professionals/KDOQI/guidelines_ckd/p7_risk_g14.htm. Accessed 9.12.2006.
112. Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 1992;15:1181-1191.
113. Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996;27:34-41.
114. Diabetes. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Accessed at: http://www.kidney.org/professionals/KDOQI/ guidelines_cvd/guide11.htm. Accessed 9.12.2006.
115. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985;28:590-596.
116. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes 1988;37:1499-1504.
117. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002;39:297-307.
118. Oyibo SO, Pritchard GM, McLay L, James E, Laing I, Gokal R, et al. Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med 2002;19:693-696.
119. Tzamaloukas AH. Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Perit Dial. 1996;12:171-175.
120. Association of chronic kidney disease with cardiovascular disease. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification Accessed at: http://www.kidney.org/ professionals/KDOQI/guidelines_ckd/p7_risk_g15.htm. Accessed 9.12.2006.
121. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35:S117-S131.
122. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-S23.
123. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561-569.
124. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003;41:925-932.
125. Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 2001;38:S4-S7.
126. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
127. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998;338:1-7.
128. Yeh S, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000;4:246-251.
129. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459.
130. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005;18:365-369.
131. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004;80:299-307.
132. Stenvinkel P, Heimburger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in endstage renal disease. Nephrol Dial Transplant 2004;19:2181-2183.
133. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003;14:1927-1939.
134. Blood pressure. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Accessed at: http://www.kidney.org/professionals/ KDOQI/guidelines_cvd/guide12.htm. Accessed 9.12.2006.
135. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-510.
136. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991;58:129-134.
137. Cannella G, La CG, Sandrini M, Gaggiotti M, Nordio G, Movilli E, et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990;34:272-278.
138. Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B. Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells. Kidney Int 1994;45:224-231.
139. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890.
140. Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993;8:1219-1222.
141. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489-493.
142. Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525-528.
143. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991;35:280-287.
144. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 1990;15:325-332.
145. Sobh MA, Abd eH I, Atta MG, Refaie AF. Effect of erythropoietin on sexual potency in chronic haemodialysis patients. A preliminary study. Scand J Urol Nephrol 1992;26:181-185.
146. Teehan B, Sigler MH, Brown JM, Benz RL, Gilgore GS, Schleifer CR, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc 1989;212:63-69.
147. Vanholder R, Van BW, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993;44:208-214.
148. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-165.
149. Wizemann V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993;64:202-206.
150. Wolcott DL, Marsh JT, La RA, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989;14:478-485.
151. Factors associated with loss of kidney function in chronic kidney disease. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Accessed at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p7_risk_g13.htm. Accessed 9.12.2006.
152. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 1994;121:62-70.
153. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-S238.
154. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825-830.
155. Grutzmacher P, Scheuermann E, Low I, Bergmann M, Rauber K, Baum R, et al. Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol 1988;66:176-184.
156. Lowrie EG, Ling J, Lew NL, Yiu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In: Friedman EA, editor. Death on hemodialysis: preventable or inevitable? Boston, MA: Kluwer Academic Publishers; 1994. pp 121-141.
157. Mocks J, Frank W, Ehmer B, Scigalla P, Quarder O. Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients. In: Koch KM, Stein G, editors. Pathogenetic and therapeutic aspects of chronic renal failure. New York: Marcel Dekker; 1997. pp 163-179.
158. Renal Physicians Association: Appropriate Preparation of the Patient for Renal Replacement Therapy: Clinical Practice Guideline No. 3. Rockville, MD: RPA; 2002.
159. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000;36:282-293.
160. Collins AJ, Li S, St PW, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473.
161. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-355.
162. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
163. Owen WF, Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003;14:S76-S80.
164. US Renal Data System. USRDS 2002 Annual report: atlas of end-stage renal disease in the United States. Bethesda, MD:National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
165. Owen WF, Jr., Szczech L, Johnson C, Frankenfield D. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Am J Kidney Dis 1999;34:S5-S11.
166. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 2006;73:289-297.
167. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-788.
168. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality
169. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-S145.
170. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 Suppl 2:ii1-47.
171. NKF-K/DOQI guidelines: anemia of chronic kidney disease: iron support. UpToDate 2006. Version 14.3. Accessed at: http://uptodateonline.com/utd/content/ topic.do?topicKey=nkf_doqi/14137&type=A&selectedTitle=165~333. Accessed 7.12.2006.
172. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: iron support: Update 2000. Accessed at: http://www.kidney.org/ professionals/kdoqi/guidelines/doqi_uptoc.html#an. Accessed 7.12.2006.
173. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl JMed 2006;355:2071-2084.
174. Remuzzi G, Ingelfinger JR. Correction of anemia-payoffs and problems. N Engl J Med 2006;355:2144-2146.
175. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
176. Berns JS, Cronin RE, Henrich WL. Erythropoietin for the anemia of chronic kidney disease. UpToDate 2006. Version 14.3. Accessed at: http://www.utdol.com/ utd/content/topic.do?topicKey=dialysis/9597&type=A&selectedTitle=18~333. Accessed 9.1.2007.
177. Nissenson AR, Anand S. Darbepoetin alfa for the management of anemia in chronic kidney disease. UpToDate 2006. Version 14.3. Accessed at: http://uptodateonline.com/utd/content/topic.do?topicKey=dialysis/39273&type= A&selected Title=1~17. Accessed 7.12.2006.
178. VHA/DoD Clinical practice guideline for management of chronic kidney disease and pre-ESRD in primary care setting. Accessed at: http://www.oqp.med. va.gov/cpg/ESRD/ESRD_cpg/algoframe.htm. Accessed 9.12.2006.
179. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999;45:243-253.
180. Cantu TG, Ellerbeck EF, Yun SW, Castine SD, Kornhauser DM. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 1992;49:2944-2948.
181. Canadian Institute for Health Information. Report, Volume 1: Dialysis and renal transplantation. Canadian organ replacement register. Ottawa: Canadian Institute for Health Information; 2000.
182. Davison SN. Quality end-of-life care in dialysis units. Semin Dial 2002;15:41-44.
183. Deoreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997;30:204-212.
184. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993;4:12-27.
185. McClellan WM, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991;44:83-89.
186. McClellan WM, Stanwyck DJ, Anson CA. Social support and subsequent mortality among patients with end-stage renal disease. J Am Soc Nephrol 1993;4:1028-1034.
187. Parkerson GR, Jr, Broadhead WE, Tse CK. Health status and severity of illness as predictors of outcomes in primary care. Med Care 1995;33:53-66.
188. Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clin Pract 2003;95:c40-c46.
189. Braveman C, Cohen LM. Discontinuation of dialysis: the role of hospice and palliative care. AAHPM Bull 2003;3:16-17.
190. Holley JL. A single-center review of the death notification form: discontinuing dialysis before death is not a surrogate for withdrawal from dialysis. Am J Kidney Dis 2002;40:525-530.
191. Holley JL. Palliative care in end-stage renal disease: focus on advance care planning, hospice referral, and bereavement. Semin Dial 2005;18:154-156.
192. Moss AH, Holley JL, Davison SN, Dart RA, Germain MJ, Cohen L, et al. Palliative care. Am J Kidney Dis 2004;43:172-173.
193. Fazekas G, Fazekas F, Schmidt R, Kapeller P, Offenbacher H, Krejs GJ. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 1995;134:83-88.
194. Madan P, Kalra OP, Agarwal S, Tandon OP. Cognitive impairment in chronic kidney disease. Nephrol Dial Transplant 2006;22:440-444.
195. Sehgal AR, Grey SF, Deoreo PB, Whitehouse PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997;30:41-49.
196. Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004;52:1863-1869.
197. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003;42:217-228.
198. Griffin MR, Ray WA, Schaffner W. Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-363.
199. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-263.
200. Greenberger NJ. Update in gastroenterology. Ann Intern Med 1997;126:221-225.
201. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998;338:727-734.
202. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swanell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med7 1998;338:719-726.